CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its βKlotho monoclonal antibody (mAb), JMT202. This molecule is intended to reduce triglyceride (TG) levels in patients suffering from hypertriglyceridemia.
JMT202, an FGFR1c/β Klotho receptor agonist, works by binding to the β Klotho protein, which specifically activates the FGFR1c/β Klotho receptor complex. This activation simulates the natural ligand FGF21 protein, thereby regulating glucose and lipid metabolism. The product holds potential for treating a range of metabolic-related diseases, including dyslipidemia, nonalcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and more. It also has the potential to be used in combination with other targeted drugs, such as GLP-1 agonists, that regulate glucose and lipid metabolism.
Preclinical studies have demonstrated that CSPC’s JMT202 boasts a favorable safety profile and a relatively long dosing interval. The molecule has shown potential to significantly reduce triglycerides and exhibits a lipid-lowering effect, underscoring its high value for clinical development.- Flcube.com
